New treatment modalities in gastrointestinal malignancies: broadening the therapeutic horizon
Rapid advances in molecular targeting, immunotherapy optimisation and novel drug classes are reshaping gastrointestinal oncology
From bottleneck to breakthrough: rethinking clinical data collection in the age of AI
Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.
ctDNA is unlocking new clinical opportunities for liquid biopsy
Testing standardisation and optimal integration for routine clinical use remain challenging
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer?
Long-term dostarlimab data suggest that immunotherapy may be used with curative intent in this difficult-to-treat population
Is there a role for intensification immunotherapy in patients with locally advanced cervical cancer?
Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours
Early-phase studies point to efficacy of a nectin-4-targeting antibody-drug conjugate in cervical cancer
In advanced or metastatic disease, bulumtatug fuvedotin shows promising efficacy and manageable safety
The antibody–drug conjugate era in gynaecological cancers
Recent approvals are driving a shift toward biomarker-informed treatment strategies, rational combinations and personalised sequencing
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
Exploiting HER2 tumour heterogeneity with digital oncology
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers
First-line dual targeting combination shows encouraging, durable responses in triple-negative breast cancer
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study